<DOC>
	<DOCNO>NCT02718898</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety study drug ixekizumab compare placebo participant moderate-to-severe genital psoriasis .</brief_summary>
	<brief_title>A Study Ixekizumab ( LY2439821 ) Participants With Moderate-to-Severe Genital Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have chronic plaque psoriasis base diagnosis chronic plaque psoriasis least 6 month baseline . Have moderatetosevere psoriasis genital area screen baseline . Have plaque psoriasis nongenital area screen baseline . Have fail respond , intolerant , least 1 topical therapy use treatment psoriasis affect genital area . Must agree use reliable method birth control , could include abstinence , study least 12 week follow last dose study drug . Pustular , erythrodermic , and/or guttate form psoriasis . History druginduced psoriasis . Have recently receive certain treatment psoriasis ( particular , within past 4 week restriction go 12 month treatment ) . Have ever receive treatment ixekizumab , secukinumab , brodalumab , another drug similar mode action . Can avoid excessive sun exposure use tan booth least 4 week prior baseline study . Are currently enrol clinical trial involve investigational product . Serious disorder illness plaque psoriasis . Active history malignant disease within 5 year prior baseline . Serious infection within last 3 month . Have receive live vaccine within 3 month baseline plan study . Have receive vaccination Bacillus CalmetteGu√©rin ( BCG ) within past year . Pregnant breastfeeding ( lactate ) woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>genital</keyword>
</DOC>